Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02143973 · ClinicalTrials.gov registry record · Phase 2
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
A Phase 2 study, sponsored by Trevi Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
NCT02143973 is a Phase 2 study that has completed, run by Trevi Therapeutics. The registered enrollment target is 167 participants.
The verdict
NCT02143973, a Phase 2 study, has completed, sponsored by Trevi Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 24 weeks.
Interventions
- DRUG nalbuphine HCl ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02143973
The ClinicalTrials.gov registry entry for NCT02143973 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trevi Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nalbuphine HCl ER is the first listed.
NCT02143973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02143973 about?
NCT02143973 is a clinical study titled "Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus". The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 24 weeks.
What is the current status of trial NCT02143973?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2014-09. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02143973?
The interventions under investigation include: nalbuphine HCl ER (DRUG).
Who is sponsoring clinical trial NCT02143973?
This trial is sponsored by Trevi Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.